Type 2 diabetes and the evolving paradigm in glucose regulation

American Journal of Managed Care

Volumn 19, Issue 3 SUPPL, 2013, Pages

  Abdul Ghani, Muhammad A ^a  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FATTY ACID; GLUCOSE; GLUCOSE TRANSPORTER; INCRETIN; INSULIN; GASTRIC INHIBITORY POLYPEPTIDE; GASTROINTESTINAL HORMONE; GLUCAGON; GLUCAGON LIKE PEPTIDE 1; SODIUM GLUCOSE COTRANSPORTER;

ADIPOCYTE; ADIPOSE TISSUE; ARTICLE; BLOOD GLUCOSE MONITORING; BRAIN; FATTY ACID BLOOD LEVEL; GASTROINTESTINAL TRACT; GLUCONEOGENESIS; GLUCOSE BLOOD LEVEL; GLUCOSE HOMEOSTASIS; GLUCOSE METABOLISM; GLUCOSE TRANSPORT; GLUCOTOXICITY; HORMONE DEFICIENCY; HUMAN; HYPERGLYCEMIA; IMPAIRED GLUCOSE TOLERANCE; INCRETIN DEFICIENCY; INSULIN BLOOD LEVEL; INSULIN RELEASE; INSULIN RESISTANCE; INSULIN SENSITIVITY; KIDNEY; LIPOTOXICITY; LIVER; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PANCREAS ISLET ALPHA CELL; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL; SKELETAL MUSCLE; SODIUM EXCRETION; APPETITE; BLOOD; DIET RESTRICTION; METABOLISM; OBESITY; PATHOPHYSIOLOGY; PHYSIOLOGY; REVIEW; DEFICIENCY;

ADIPOCYTES; APPETITE; BRAIN; DIABETES MELLITUS, TYPE 2; FASTING; FATTY ACIDS, NONESTERIFIED; GASTRIC INHIBITORY POLYPEPTIDE; GASTROINTESTINAL HORMONES; GLUCAGON; GLUCAGON-LIKE PEPTIDE 1; GLUCAGON-SECRETING CELLS; GLUCOSE; HUMANS; INSULIN RESISTANCE; INSULIN-SECRETING CELLS; KIDNEY; LIVER; MUSCLE, SKELETAL; OBESITY; SODIUM-GLUCOSE TRANSPORT PROTEINS;

EID: 84891649995     PISSN: 10880224     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (56)

1. Powers AC. Diabetes mellitus. In: Longo DL, Fauci AS, Kasper DL, Hauser SL, Jameson JL, Loscalzo J, eds. Harrison's Principles of Internal Medicine. 18th ed. New York, NY: McGraw-Hill; 2012. http://www.accessmedicine.com/content. aspx?aID=9141196. Accessed March 6, 2012.
2. DeFronzo RA. Banting lecture: from the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus. Diabetes. 2009;58(4):773-795.
3. DeFronzo RA. Pathogenesis of type 2 diabetes mellitus. Med Clin North Am. 2004;88:787-835. (Pubitemid 39090340)
4. Saad MF, Knowler WC, Pettitt DJ, Nelson RG, Mott DM, Bennett PH. The natural history of impaired glucose tolerance in the Pima Indians. N Engl J Med. 1988;319:1500-1505.
5. Petersen KF, Dufour S, Befroy D, Garcia R, Shulman GI. Impaired mitochondrial activity in the insulin-resistant offspring of patients with type 2 diabetes. N Engl J Med. 2004;350:664-671. (Pubitemid 38364625)
6. Neeland IJ, Turer AT, Ayers CR, et al. Dysfunctional adiposity and the risk of prediabetes and type 2 diabetes in obese adults. JAMA. 2012;308(11):1150-1159.
7. Rossetti L, Giaccari A, DeFronzo RA. Glucose toxicity. Diabetes Care. 1990;13:610-630. (Pubitemid 20169143)
8. DeFronzo RA, Ferrannini E, Simonson DC. Fasting hyperglycemia in non-insulin dependent diabetes mellitus: contributions of excessive hepatic glucose production and impaired tissue glucose uptake. Metabolism. 1989;38:387-395. (Pubitemid 19105727)
9. Groop LC, Bonadonna RC, DelPrato S, et al. Glucose and free fatty acid metabolism in non-insulin-dependent diabetes mellitus: evidence for multiple sites of insulin resistance. J Clin Invest. 1989;84(1):205-213. (Pubitemid 19170111)
10. Watanabe RM, Valle T, Hauser ER, et al. Familiarity of quantitative metabolic traits in Finnish families with non-insulin dependent diabetes mellitus: Finland-United States Investigation of NIDDM Genes (FUSION) Study Investigators. Hum Hered. 1999;39:159-168.
11. Abdul-Ghani MA, DeFronzo RA. Pathogenesis of insulin resistance in skeletal muscle. J Biomed Biotechnol. 2010;2010:476279.
12. DeFronzo RA, Gunnarsson R, Bjorkman O, Olsson M, Wahren J. Effects of insulin on peripheral and splanchnic glucose metabolism in non-insulin-dependent (type II) diabetes mellitus. J Clin Invest. 1985;76:149-155. (Pubitemid 15240430)
13. DeFronzo RA, Ferrannini E. Regulation of intermediatory metabolism during fasting and refeeding. In: DeGroot LJ, Jameson JL, eds. Endocrinology. Philadelphia, PA: Elsevier; 2006:1015-1043.
14. Aronoff SL, Berkowitz K, Shreiner B, et al. Glucose metabolism and regulation: beyond insulin and glucagon. Diabetes Spectrum. 2004;17(3):183-190.
15. Girard J. The inhibitory effects of insulin on hepatic glucose production are both direct and indirect. Diabetes. 2006;55(suppl 2):S65-S69. (Pubitemid 44927034)
16. Hu FB. Globalization of diabetes: the role of diet, lifestyle, and genes. Diabetes Care. 2011;34:1249-1257.
17. DeFronzo RA, Soman V, Sherwin RS, et al. Insulin binding to monocytes and insulin action in human obesity, starvation, and refeeding. J Clin Invest. 1978:204-213. (Pubitemid 8367354)
18. Garcia-Estevez DA, Araujo-Vilar D, Saavedra-Gonzalez A, et al. Analysis of the relationship between body mass index, insulin resistance, and beta-cell function: a crosssectional study using the minimal model. Metabolism. 2004;53(11):1462-1466. (Pubitemid 39410387)
19. Bray GA. Medical consequences of obesity. J Clin Endocrinol Metab. 2004;89(6):2583-2589. (Pubitemid 38766335)
20. Corpeleijn E, Saris WHM, Blaak EE. Metabolic flexibility in the development of insulin resistance and type 2 diabetes: effects of lifestyle. Obes Rev. 2009;10:178-193.
21. Greco AV, Mingrone G, Giancaterini A, et al. Insulin resistance in morbid obesity: reversal with intramyocellular fat depletion. Diabetes. 2002;51:144-151. (Pubitemid 34517991)
22. Pan DA, Lillioja S, Kriketos AD, et al. Skeletal muscle triglyceride levels are inversely related to insulin action. Diabetes. 1997;46(6):983-988. (Pubitemid 27220998)
23. Krssak M, Petersen KF, Dresner A, et al. Intramyocellular lipid concentrations are correlated with insulin sensitivity in humans: a 1H NMR spectroscopy study. Diabetologia. 1999;42:113-116. (Pubitemid 29039748)
24. Roden M, Price TB, Perseghin G, et al. Mechanism of free fatty acid-induced insulin resistance in humans. J Clin Invest. 1996;97:2859-2865. (Pubitemid 26197099)
25. Kashyap S, Belfort R, Gastaldelli A, et al. A sustained increase in plasma free fatty acids impairs insulin secretion in nondiabetic subjects genetically predisposed to develop type 2 diabetes. Diabetes. 2003;52:2461-2474. (Pubitemid 37210533)
26. DeFronzo RA. Dysfunctional fat cells, lipotoxicity, and type 2 diabetes. Int J Clin Pract Suppl. 2004;143:9-21.
27. Bajaj M, Suraamornkul S, Romanelli A, et al. Effect of sustained reduction in plasma free fatty acid concentration on intramuscular long chain-fatty acyl-CoAs and insulin action in patients with type 2 diabetes. Diabetes. 2005;54:3148-3153. (Pubitemid 43334368)
28. Paulisso G, Tagliamonte MR, Rizzo MR, et al. Lowering fatty acids potentiates acute insulin response in first degree relatives of people with type II diabetes. Diabetologia. 1998;41:1127-1132. (Pubitemid 28449076)
29. Santomauro ATMG, Boden G, Silva MER, et al. Overnight lowering of free fatty acids with acipimox improves insulin resistance and glucose tolerance in obese diabetic and nondiabetic subjects. Diabetes. 1999;48:1836-1841. (Pubitemid 29415205)
30. Bays H, Mandarino L, DeFronzo RA. Role of the adipocyte, free fatty acids, and ectopic fat in pathogenesis of type 2 diabetes mellitus: peroxisomal proliferator-activated receptor agonists provide a rational therapeutic approach. J Clin Endocrinol Metab. 2004;89(2):463-478. (Pubitemid 38269844)
31. Porte D. Central regulation of energy homeostasis. Diabetes. 2006;55(suppl 2):S155-S160.
32. Matsuda M, Liu Y, Mahankali S, et al. Altered hypothalamic function in response to glucose ingestion in obese humans. Diabetes. 1999;48:1801-1806. (Pubitemid 29415200)
33. van Raalte DH, Diamant M. Glucolipotoxicity and beta cells in type 2 diabetes mellitus: target for durable therapy? Diabetes Res Clin Pract. 2011;93S:S37-S46.
34. Vauhkonen I, Niskanen L, Vanninen E, Kainulainen S, Uusitupa M, Laakso M. Defects in insulin secretion and insulin action in noninsulin-dependent diabetes mellitus are inherited: metabolic studies on offspring of diabetic probands. J Clin Invest. 1998;101(1):86-96. (Pubitemid 28058907)
35. Patane G, Anello M, Piro S, Vigneri R, Purrello F, Rabuazzo AM. Role of ATP production and uncoupling protein-2 in the insulin secretory defect induced by chronic exposure to high glucose or free fatty acids and effects of peroxisome proliferator-activated receptor-β inhibition. Diabetes. 2002;51:2749-2756. (Pubitemid 34970928)
36. Gastaldelli A, Ferrannini E, Miyazaki Y, et al. Thiazolidinediones improve α-cell function in type 2 diabetic patients. Am J Physiol Endocrinol Metab. 2007;292:E871-E883. (Pubitemid 46411067)
37. Rossetti L, Shulman GI, Zawalich W, DeFronzo RA. Effect of chronic hyperglycemia on in vivo insulin secretion in partially pancreatectomized rats. J Clin Invest. 1987;80:1037-1044. (Pubitemid 18075639)
38. Leahy JL, Cooper HE, Deal DA, et al. Chronic hyperglycemia is associated with impaired glucose influence on insulin secretion. J Clin Invest. 1986;77:908-915.
39. Nauck M, Stockmann F, Ebert R, Creutzfeldt W. Reduced incretin effect in type 2 (non-insulin-dependent) diabetes. Diabetologia. 1986;29:46-52. (Pubitemid 16162741)
40. Kim W, Egan JM. The role of incretins in glucose homeostasis and diabetes treatment. Pharmacol Rev. 2008;60:470-512.
41. Meier JJ, Nauck MA. Incretins and the development of type 2 diabetes. Curren Diab Reports. 2006;6:194-201.
42. Holst JJ, Gromada J. Role of incretin hormones in the regulation of insulin secretion in diabetic and nondiabetic humans. Am J Physiol Endocrinol Metab. 2004;287:E199-E206. (Pubitemid 38943883)
43. Vilsbøll T, Krarup T, Deacon CF, Madsbad S, Holst JJ. Reduced postprandial concentrations of intact biologically active glucagonlike peptide 1 in type 2 diabetic patients. Diabetes. 2001;50(3):609-613. (Pubitemid 32195226)
44. Nauck MA, Heimesaat MM, Orskov C, Holst JJ, Ebert R, Creutzfeldt W. Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus. J Clin Invest. 1993;91:301-307. (Pubitemid 23037285)
45. Hojberg PV, Vilsbøll T, Rabol R, et al. Four weeks of near-normalisation of blood glucose improves the insulin response to glucagonlike peptide-1 and glucose-dependent insulinotropic polypeptide in patients with type 2 diabetes. Diabetologia. 2009;52:199-207.
46. Matsuda M, DeFronzo RA, Glass L, et al. Glucagon dose response curve for hepatic glucose production and glucose disposal in type 2 diabetic patients and normal individuals. Metabolism. 2002;51:1111-1119.
47. Baron AD, Schaeffer L, Shragg P, Kolterman OG. Role of hyperglucagonemia in maintenance of increased rates of hepatic glucose output in type II diabetics. Diabetes. 1987;36:274-283. (Pubitemid 18028415)
48. Petersen KF, Sullivan JT. Effects of a novel glucagon receptor antagonist (Bay 27-9955) on glucagon-stimulated glucose production in humans. Diabetologia. 2001;44:2018-2024. (Pubitemid 33124047)
49. Abdul-Ghani MA, DeFronzo RA. Inhibition of renal glucose reabsorption: a novel strategy for achieving glucose control in type 2 diabetes mellitus. Endocr Pract. 2008;14:782-790.
50. DeFronzo RA, Davidson JA, Del Prato S. The role of the kidneys in glucose homeostasis: a new path towards normalizing glycaemia. Diabetes Obes Metab. 2012;14(1):5-14.
51. Wright EM, Loo DD, Hirayama BA. Biology of human sodium glucose transporters. Physiol Rev. 2011;91:733-794.
52. Vallon V, Platt KA, Cunard R, et al. SGLT2 mediates glucose reabsorption in the early proximal tubule. J Am Soc Nephrol. 2011;22:104-112.
53. Wright EM, Hirayama BA, Loo DF. Active sugar transport in health and disease. J Intern Med. 2007;261:32-43. (Pubitemid 46046470)
54. Abdul-Ghani MA, Norton L, Defronzo RA. Role of sodium-glucose cotransporter 2 (SGLT 2) inhibitors in the treatment of type 2 diabetes. Endocr Rev. 2011;32:515-531.
55. Rahmoune H, Thompson PW, Ward JM, et al. Glucose transporters in human renal proximal tubular cells isolated from the urine of patients with non-insulin-dependent diabetes. Diabetes. 2005;54:3427-3434. (Pubitemid 43334332)
56. Thomson SC, Rieg T, Miracle C, et al. Acute and chronic effects of SGLT2 blockade on glomerular and tubular function in the early diabetic rat. Am J Physiol Regul Integr Comp Physiol. 2012;302:R75-R83.